Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 4/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 2/20 | 1.00 |
| ▸ | ALPI | P09923 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | XIAP | P98170 | 1/20 | 1.00 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.69 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.69 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.69 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | LTA4H | P09960 | 1/20 | 0.59 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | LCK | P06239 | 1/20 | 0.58 |
| ▸ | FYN | P06241 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dl-Phenylalanine SCHEMBL15671104 | 1.00 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL16398196 | 1.00 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL1449124 | 1.00 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL16398197 | 1.00 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL8119 | 1.00 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL23159186 | 1.00 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL43671 | 1.00 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL8118 | 1.00 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| D-Phenylalanine SCHEMBL837632 | 1.00 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL1331985 | 1.00 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116730969-A | Beta-lapachone-amino acid conjugate, and preparation method and application thereof | 中国药科大学 | 2023-09-12 | — | — | CN | claimed |
| CN-115046932-A | Chiral molecular sensor based on metal nanosphere trimer and identification method | 西北工业大学 | 2022-09-13 | — | — | CN | claimed |
| WO-2019216675-A1 | EPITOPE OF REGULATORY T CELL SURFACE ANTIGEN AND ANTIBODY SPECIFICALLY BINDING THERETO | 주식회사 굳티셀 (KR) | 2019-11-14 | — | — | WO | claimed |
| CN-101781242-A | Method for preparing phthaloylamino acid | UNIV SHAANXI SCIENCE & TECH | 2010-07-21 | — | — | CN | claimed |
| CN-101781325-A | Gallium salicylaldehyde amino acid Schiff base quaternary coordination compound, preparation method and application thereof | UNIV BEIJING NORMAL | 2010-07-21 | — | — | CN | claimed |
| CN-116730969-B | Beta-lapachone-amino acid conjugate, and preparation method and application thereof | 中国药科大学 | 2024-04-19 | — | — | CN | disclosed |
| WO-2024020635-A1 | EXTRACELLULAR MATRIX HYDROGELS | THE UNIVERSITY OF NEWCASTLE (AU) | 2024-02-01 | — | — | WO | disclosed |
| CN-116730969-A | Beta-lapachone-amino acid conjugate, and preparation method and application thereof | 中国药科大学 | 2023-09-12 | — | — | CN | disclosed |
| US-20230152235-A1 | IMPROVED BIOMOLECULE DETECTION USING SURFACE-ENHANCED RAMAN SPECTROSCOPY | NOSTICS B.V. (NL) | 2023-05-18 | — | — | US | disclosed |
| CN-112543752-B | Linker, antibody conjugate drug containing linker and use of linker | 中国人民解放军军事科学院军事医学研究院 | 2023-04-18 | — | — | CN | disclosed |
| CN-114062531-A | Rheumatoid arthritis early synovial fluid diagnostic kit and application thereof | 山东第一医科大学(山东省医学科学院) | 2022-02-18 | — | — | CN | disclosed |
| US-20210061861-A1 | D-PEPTIDIC COMPOUNDS FOR VEGF | REFLEXION PHARMACEUTICALS, INC. | 2021-03-04 | — | — | US | disclosed |
| CN-1058486-C | Separating method for unequal-quantity antipode of phenylalanine | UNIV WUHAN (CN) | 2000-11-15 | — | — | CN | disclosed |
| CN-1271250-A | Polyamine treatment of neurological disorders | MICHAEL A MURPHY (US) | 2000-10-25 | — | — | CN | disclosed |
| EP-1017275-A1 | POLYAMINE TREATMENT OF NEUROLOGICAL DISORDERS | Murphy, Michael A. (US) | 2000-07-12 | — | — | EP | disclosed |
| CN-1235164-A | Peptide for vaccine of schistosomiasis | UNIV BEIJING MEDICAL (CN) | 1999-11-17 | — | — | CN | disclosed |
| US-5906996-A | Tetramine treatment of neurological disorders | MURPHY MICHAEL A (US) | 1999-05-25 | — | — | US | disclosed |
| CN-1211567-A | Separating method for unequal-quantity antipode of phenylalanine | UNIV WUHAN (CN) | 1999-03-24 | — | — | CN | disclosed |
| WO-1999008519-A1 | POLYAMINE TREATMENT OF NEUROLOGICAL DISORDERS | MURPHY MICHAEL A (US) | 1999-02-25 | — | — | WO | disclosed |
| US-4745210-A | AMIDATION OF PHENYLALANINE WITH ANHYDRIDE | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1988-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061861-A1 | D-PEPTIDIC COMPOUNDS FOR VEGF | VEGFA, KDR, FLT1 | SLC7A5 758/4885PTGS1 4034/4885ALPI 4810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.